Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.76 |
| ▸ | TP53 | P04637 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | STAT3 | P40763 | 2/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.76 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.76 |
| ▸ | FOXO3 | O43524 | 1/20 | 0.76 |
| ▸ | MITF | O75030 | 1/20 | 0.76 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.76 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.76 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.76 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.76 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173088 | 0.93 | ALDH1A1 (0.82) | ALDH1A1TP53SMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL25283508 | 0.93 | ALDH1A1 (0.82) | ALDH1A1TP53SMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL98524 | 0.90 | ALDH1A1 (0.77) | ALDH1A1TP53SMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL12675623 | 0.89 | ALDH1A1 (0.87) | ALDH1A1TP53SMN1; SMN2MAPTHSD17B10 | |
| Piplartine SCHEMBL173092 | 0.86 | ALDH1A1 (1.00) | ALDH1A1TP53SMN1; SMN2MAPTHSD17B10 | |
| Piplartine SCHEMBL2465593 | 0.86 | ALDH1A1 (1.00) | ALDH1A1TP53SMN1; SMN2MAPTHSD17B10 | |
| (Z)-Piplartine SCHEMBL30013548 | 0.86 | ALDH1A1 (1.00) | ALDH1A1TP53SMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL17472039 | 0.85 | ALDH1A1 (0.70) | ALDH1A1TP53SMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL98534 | 0.84 | ALDH1A1 (0.75) | ALDH1A1TP53SMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL15432074 | 0.83 | ALDH1A1 (0.67) | ALDH1A1TP53SMN1; SMN2MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108923-B2 | Compounds, compositions, and methods for cancer therapy | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140024639-A1 | Compounds, Compositions, and Methods for Cancer Therapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-01-23 | — | — | US | disclosed |
| US-20130237539-A1 | Compounds and Compositions for Treating Cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130203757-A1 | Compounds And Compositions For Treating Cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2013-08-08 | — | — | US | disclosed |
| US-8349832-B2 | Compounds and compositions for treating cancer | Canthera Therapeutics (US) | 2013-01-08 | — | — | US | disclosed |
| US-8318737-B2 | Compounds and compositions for treating cancer | CANTHERA THERAPEUTICS INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120157455-A1 | Compounds And Compositions For Treating Cancer | CANTHERA THERAPEUTICS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120059004-A1 | Compounds And Compositions For Treating Cancer | CANTHERA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110053938-A1 | Compounds and Compositions For Treating Cancer | CANTHERA THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20090312373-A1 | METHODS FOR THE TREATMENT OF CANCER USING PIPERLONGUMINE AND PIPERLONGUMINE ANALOGS | THE GENERAL HOSPITAL CORPORATION (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312373-A1 | METHODS FOR THE TREATMENT OF CANCER USING PIPERLONGUMINE AND PIPERLONGUMINE ANALOGS | VHL, DHFR, THPO | ALDH1A1 305/4885TP53 54/4885SMN1; SMN2 4212/4885 |
| US-20140024639-A1 | Compounds, Compositions, and Methods for Cancer Therapy | MCL1, TP53, VHL | ALDH1A1 710/4885TP53 2/4885SMN1; SMN2 3402/4885 |
| US-20120059004-A1 | Compounds And Compositions For Treating Cancer | NQO1, HCCS, TXNRD2 | ALDH1A1 503/4885TP53 7/4885SMN1; SMN2 1285/4885 |
| US-20130203757-A1 | Compounds And Compositions For Treating Cancer | NQO1, HCCS, TXNRD2 | ALDH1A1 503/4885TP53 7/4885SMN1; SMN2 1285/4885 |
| US-20110053938-A1 | Compounds and Compositions For Treating Cancer | NQO1, HCCS, TXNRD2 | ALDH1A1 503/4885TP53 7/4885SMN1; SMN2 1285/4885 |
| US-20130237539-A1 | Compounds and Compositions for Treating Cancer | NQO1, HCCS, TXNRD2 | ALDH1A1 503/4885TP53 7/4885SMN1; SMN2 1285/4885 |
| US-20120157455-A1 | Compounds And Compositions For Treating Cancer | NQO1, HCCS, TXNRD2 | ALDH1A1 503/4885TP53 7/4885SMN1; SMN2 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.